{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:31:41Z","timestamp":1790195501495,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.diabres.2018.03.027","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T13:53:27Z","timestamp":1522245207000},"page":"118-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes \u2013 A systematic review"],"prefix":"10.1016","volume":"140","author":[{"given":"Karin","family":"R\u00e5dholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason HY","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muh Geot","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Foote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Fulcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.diabres.2018.03.027_b0005","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.diabres.2018.03.027_b0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.diabres.2018.03.027_b0015","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2018.03.027_b0020","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2106\/00004623-194830040-00020","article-title":"Bone disturbances in injury to spinal cord and cauda equina (paraplegia): their prevention by ambulation","volume":"30A","author":"Abramson","year":"1948","journal-title":"J Bone Joint Surg"},{"key":"10.1016\/j.diabres.2018.03.027_b0025","unstructured":"U.S. Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood: Food and Drug Administration; 2015 https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm446845.htm."},{"issue":"9","key":"10.1016\/j.diabres.2018.03.027_b0030","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2018.03.027_b0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2018.03.027_b0040","series-title":"FDA briefing document NDA 202293 dapagliflozin oral tablets 5 AND 10 MG","author":"Bristol Myers Squibb","year":"2013"},{"issue":"7","key":"10.1016\/j.diabres.2018.03.027_b0045","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2018.03.027_b0050","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2018.03.027_b0055","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2018.03.027_b0060","series-title":"Labour and welfare, report on the deliberation results - ipragliflozin","author":"Evaluation and Licensing Division PaFSBMoH","year":"2013"},{"key":"10.1016\/j.diabres.2018.03.027_b0065","series-title":"Labour and welfare, report on the deliberation results - luseogliflozin","author":"Evaluation and Licensing Division PaFSBMoH","year":"2014"},{"key":"10.1016\/j.diabres.2018.03.027_b0070","series-title":"FDA briefing document NDA 204042 invokana (canagliflozin) tablets","author":"Food and Drug Administration","year":"2013"},{"key":"10.1016\/j.diabres.2018.03.027_b0075","unstructured":"Boehringer Ingelheim International. Assessment report Jardiance International non-proprietary name: empagliflozin Procedure No. EMEA\/H\/C\/002677\/0000. UK: European Medicines Agency; 2014."},{"key":"10.1016\/j.diabres.2018.03.027_b0080","series-title":"Labour and welfare, report on the deliberation results - tofogliflozin","author":"Evaluation and Licensing Division PaFSBMoH","year":"2014"},{"key":"10.1016\/j.diabres.2018.03.027_b0085","series-title":"Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus NDA 204042","author":"Janssen Research & Development","year":"2013"},{"key":"10.1016\/j.diabres.2018.03.027_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"9","key":"10.1016\/j.diabres.2018.03.027_b0095","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0895-4356(02)00443-2","article-title":"Hazard rate ratio and prospective epidemiological studies","volume":"55","author":"Symons","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.diabres.2018.03.027_b0100","year":"2005"},{"issue":"4","key":"10.1016\/j.diabres.2018.03.027_b0105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdi.12453","article-title":"Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period","volume":"7","author":"Araki","year":"2016","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.diabres.2018.03.027_b0110","author":"Frias","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.diabres.2018.03.027_b0115","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dc16-0522","article-title":"Initial combination of empagliflozin and metformin in patients with type 2 diabetes","volume":"39","author":"Hadjadj","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2018.03.027_b0120","doi-asserted-by":"crossref","first-page":"88e66","DOI":"10.1016\/j.clinthera.2015.10.025","article-title":"Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus","volume":"38","author":"Haneda","year":"2016","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.diabres.2018.03.027_b0125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"89","key":"10.1016\/j.diabres.2018.03.027_b0130","article-title":"Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus","volume":"15","author":"Inagaki","year":"2016","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.diabres.2018.03.027_b0135","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/dom.12745","article-title":"Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study","volume":"18","author":"Ishihara","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2018.03.027_b0140","first-page":"08","article-title":"Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial","volume":"08","author":"Kadowaki","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2018.03.027_b0145","unstructured":"Lauring B, Eldor R, Liu J, Dagogo-Jack S, Amorin G, Johnson J, et al. Efficacy and safety of ertugliflozin in subjects with type 2 diabetes mellitus inadequately controlled on the dual combination of metformin and sitagliptin: The VERTIS SITA2 trial. In: Diabetologia. 2016; conference: 52nd annual meeting of the European association for the study of diabetes, EASD. 2016. Germany. Conference start: 20160912. Conference end: 20160916 59(1 Supplement 1):S93."},{"issue":"3","key":"10.1016\/j.diabres.2018.03.027_b0150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/dc13-2762","article-title":"Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study","volume":"38","author":"Leiter","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2018.03.027_b0155","doi-asserted-by":"crossref","first-page":"5347262","DOI":"10.1155\/2016\/5347262","article-title":"Influence of dapagliflozin on glycemic variations in patients with newly diagnosed type 2 diabetes mellitus","volume":"2016","author":"Li","year":"2016","journal-title":"J Diabetes Res"},{"issue":"3","key":"10.1016\/j.diabres.2018.03.027_b0160","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/jdi.12422","article-title":"Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial","volume":"7","author":"Lu","year":"2016","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.diabres.2018.03.027_b0165","unstructured":"Mansfield T, Henry RR, Strange P, Zhou R, Zhuplatov SB, Klein D, et al. Effects of dapagliflozin (DAPA), a sodium glucose cotransporter 2 inhibitor, on 24-hour glycaemic control in patients with type 2 diabetes. In: Diabetologia. 2016; conference: 52nd annual meeting of the European association for the study of diabetes, EASD. 2016. Germany. Conference start: 20160912. Conference end: 20160916 59(1 Supplement 1):S339."},{"issue":"11","key":"10.1016\/j.diabres.2018.03.027_b0170","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/dom.12737","article-title":"Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52weeks in patients with type 2 diabetes","volume":"18","author":"Mathieu","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2018.03.027_b0175","first-page":"14","article-title":"The albuminuria lowering response to dapagliflozin is variable and reproducible between individual patients","volume":"14","author":"Petrykiv","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.diabres.2018.03.027_b0180","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.12684","article-title":"Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin","volume":"18","author":"Rodbard","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2018.03.027_b0185","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-015-0314-0","article-title":"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: A double-blind extension of a Phase III randomized controlled trial","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.diabres.2018.03.027_b0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc15-1736","article-title":"Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2018.03.027_b0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/dc16-1347","article-title":"Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial","volume":"40","author":"Softeland","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2018.03.027_b0200","first-page":"30","article-title":"Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP\/INS): Results of a 16 week randomized, double-blind, placebo-controlled multicentre trial","volume":"30","author":"Terauchi","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2018.03.027_b0205","doi-asserted-by":"crossref","DOI":"10.1111\/dom.12888","article-title":"Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone","author":"Terra","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2018.03.027_b0210","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jch.12747","article-title":"Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension","volume":"18","author":"Townsend","year":"2016","journal-title":"J Clin Hypertens (Greenwich, Conn)"},{"issue":"1 Supplement 1","key":"10.1016\/j.diabres.2018.03.027_b0215","first-page":"S346","article-title":"Effects of dapagliflozin on weight loss and metabolic changes in type 2 diabetes patients fasting in the month of Ramadan","volume":"59","author":"Wan Seman","year":"2016","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.diabres.2018.03.027_b0220","first-page":"211","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.diabres.2018.03.027_b0225","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","article-title":"Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade","volume":"25","author":"Weber","year":"2016","journal-title":"Blood Press"},{"issue":"6","key":"10.1016\/j.diabres.2018.03.027_b0230","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/1753-0407.12357","article-title":"Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial","volume":"8","author":"Yang","year":"2016","journal-title":"J Diabetes"},{"issue":"4","key":"10.1016\/j.diabres.2018.03.027_b0235","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.diabres.2018.03.027_b0240","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/dc15-1251","article-title":"Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program","volume":"38","author":"Erondu","year":"2015","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2018.03.027_b0245","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.diabres.2018.03.027_b0250","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"154","key":"10.1016\/j.diabres.2018.03.027_b0255","article-title":"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.diabres.2018.03.027_b0260","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00592-016-0928-z","article-title":"Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials","volume":"54","author":"Monami","year":"2017","journal-title":"Acta Diabetol"},{"issue":"6","key":"10.1016\/j.diabres.2018.03.027_b0265","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484633","article-title":"The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics","volume":"46","author":"Jardine","year":"2017","journal-title":"Am J Nephrol"},{"issue":"10","key":"10.1016\/j.diabres.2018.03.027_b0270","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.diabres.2018.03.027_b0275","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.diabres.2018.03.027_b0280","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"The Lancet Diabetes Endocrinol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822717317849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822717317849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T19:31:27Z","timestamp":1534966287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822717317849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":56,"alternative-id":["S0168822717317849"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2018.03.027","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes \u2013 A systematic review","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2018.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}